TOP LINE

Photo: Alain Lamproye

EcosystèmeFrance

The French CRO specialized, among other things, in analyses for gene therapies can now analyze clinical samples coming from across the Atlantic.GenoSafe, a CRO originating from the AFM-Téléthon ecosystem, is developing its international positioning.

EcosystèmeFrance

As of Monday, May 18, Biotech Finances will go live with a new version of its website and launch a mobile application. A redesign conceived to make access to content easier and to broaden its international reach, while maintaining a high value-added

ESSENTIEL

EcosystèmeFrance

WORLD(United States/Medtech/Urology) - Rivermark Medical closes a $20M Series D led by Andera Partners, with support from existing investors and a strategic investor (undisclosed), to accelerate development of its FloStent system for benign prostatic

TOP LINE

EcosystèmeInternational

We were worried about the FDA with arrivals (Vinay Prasad), departures (Richard Padzur, Vinay Prasad), reversals and returns (Vinay Prasad), then again resignations (Vinay Prasad), strange decisions and ever more indecision. But today the rag is burn

EcosystèmeFrance

Health research depends heavily on residual human biological samples, but it is today hindered by a bureaucracy deemed "disproportionate." Backed by the Observatoire du droit de la recherche en santé (ODRES), their appeal targets the CODECOH procedur

ESSENTIEL

EcosystèmeFrance

WORLD(United States/Biotech/Microbiome & IO) - Kanvas Biosciences closes a $48M Series A co‑led by DCVC and Lions Capital, followed by the Gates Foundation, ATHOS KG, Germin8, Ki Tua Fund and Pangaea Ventures. This round brings total funding to $78M

EcosystèmeFrance

The association's new appel à manifestation d’intérêt (AMI) targets innovative projects using artificial intelligence to reduce the diagnostic odyssey in rare diseases. Barely a few months old and already a 2nd AMI! The association RADAR (Rare diseas

ESSENTIEL

EcosystèmeFrance

WORLD(United States/Biotech/Proteomics) – Alamar Biosciences completes its IPO on Nasdaq (ticker ALMR), with shares issued at $17 and a first trade at $22.6, valuing the precision proteomics company at roughly $1.5B. Powered by its proprietary NULISA

Ecosystème

The return of volatility linked to the war in the Middle East caught up with listed biotechs in the first quarter of 2026. The rise in oil prices translated into a rise in interest rates, penalizing growth stocks. Outlooks remain positive, with the s

EcosystèmeFrance

On 16 December 2025, the European Commission proposed the "European Biotech Act" (Biotech Act I), a proposal forming the first phase of a strategic initiative intended to strengthen the position of the European Union ("EU") on the international stage

EcosystèmeFrance

The 5th edition of the Trophées de la HealthTech by France Biotech delivered a clear message: the French ecosystem is teeming with high-potential projects.At the Théâtre des Variétés in Paris, the HealthTech Trophies 2026 ceremony felt like a collect

WORLD(United States; Israel/medtech/lymphedema) - Sub-Q Bionics has raised $1.5M in pre-seed funding from the Mayo Clinic, Yeda (Weizmann), private investors (undisclosed) and the Israel Innovation Authority. The company is developing a subcutaneous